← Cancer trial database
Trial Spotlight
Non-small cell lung cancer

Phase 3 PF-08634404 PD-1×VEGF bispecific antibody plus chemo vs pembrolizumab in 1L NSCLC

Trial status

Currently Recruiting

Status as of

Got an update?
Trial ID
NCT07222566 on ClinicalTrials.gov
Cancer type
Non-Small Cell Lung Cancer (NSCLC)
Stage of research
Registrational
Location
17 locations (US including Puerto Rico, Canada, and Japan)
Published in
New in Oncology - Feb 24, 2026

This Phase 3, double-blind, randomized Pfizer study tests whether PF-08634404—a bispecific antibody targeting PD-1 (checkpoint inhibition to restore T-cell activity) and VEGF (anti-angiogenesis/immune–microenvironment modulation)—combined with platinum-based chemotherapy improves outcomes versus pembrolizumab (Merck’s PD-1 monoclonal antibody) plus the same chemotherapy in untreated, unresectable stage IIIB/IIIC or metastatic stage IV NSCLC. The trial is split by histology: Part 1 enrolls squamous NSCLC and Part 2 enrolls non-squamous NSCLC, with maintenance continuing as PF-08634404 or pembrolizumab (plus a chemo component in non-squamous maintenance per protocol). It focuses on patients without known actionable genomic alterations and who are not candidates for curative surgery or chemoradiotherapy—i.e., the typical “first-line metastatic” population where regimen selection hinges on histology and biomarker/genomic exclusions. The commercial/scientific angle is a head-to-head attempt to replace the widely used pembrolizumab+chemo backbone by building VEGF blockade into the same molecule as PD-1 inhibition, a class approach also being pursued by other PD-(L)1×VEGF bispecific programs. Today’s care for these patients is pembrolizumab plus platinum doublet chemotherapy (with pemetrexed commonly used in non-squamous) followed by pembrolizumab-based maintenance, while bevacizumab/anti-VEGF strategies are used more selectively depending on regimen, histology, and bleeding risk.

More on NCT07222566

More in non-small cell lung cancer

See all entries in non-small cell lung cancer →